LANSING, Mich., May 7, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company"), the leading developer of advanced spider silk based fibers, today announced plans to launch its initial commercial production of Monster Silk™. The announcement of the Company's decision to launch commercial production follows the early successes of its of Monster Silk™ pilot production program.
"We have received strong indications of interest from potential customers and potential commercialization partners," said, CEO and founder, Kim Thompson. "Many of these companies have been very patient with the fact that our laboratory production has been limited and can not satisfy their demand for quantities of material sufficient to run test weaves and end product testing.
"Moving from our pilot production program to commercial production is a very big jump, but it is also a natural progression," continued Thompson. "We have been laying the groundwork for this expansion over the last twelve months. We are confident in the decision and we are hopeful that we can accomplish the launch during the third and fourth quarters. Our plan is to begin commercial production to meet customer needs, secure future orders and capture market share in the technical textiles market."
Kraig's pilot production program will continue to run, in order to supply continuing data and help grow the Company's production capacity.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com
Source:Kraig Biocraft Laboratories, Inc